Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02326220 · ClinicalTrials.gov registry record · Phase 3

Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy

A Phase 3 study of Heterozygous Familial Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
62
Enrollment target
13
Study locations

NCT02326220 is a Phase 3 study of Heterozygous Familial Hypercholesterolemia that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 62 participants, below the 248-participant average among 4 other Heterozygous Familial Hypercholesterolemia trials with a reported enrollment target (75% lower). The trial reports 13 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02326220, a Phase 3 study of Heterozygous Familial Hypercholesterolemia, has completed, sponsored by Regeneron Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
62 participants
Enrollment target
13
Study locations

Study Summary

The primary objective of the study is to evaluate the effect of alirocumab 150 mg every 2 weeks (Q2W) in comparison with placebo on the frequency of low-density lipoprotein (LDL) apheresis treatments in participants with heterozygous familial hypercholesterolemia (HeFH) undergoing weekly or bi-weekly LDL apheresis therapy.

Conditions Studied

Heterozygous Familial Hypercholesterolemia

Interventions

  • DRUG Placebo
  • DRUG Alirocumab

Study Locations (13)

Other

  • - Berlin
  • - Göttingen
  • - Muenchen (2 Locations)
  • - Passau
  • - Rostock

Colorado

  • - Aurora

Connecticut

  • - Hartford

Kansas

  • - Kansas City

Maine

  • - Scarborough

Minnesota

  • - Rochester

Oregon

  • - Portland

Pennsylvania

  • - Philadelphia

Trial Details

FieldValue
Enrollment Target 62 participants
Start Date 2015-03-31
Est. Completion 2016-04-30
Phase Phase 3

Sponsor

Regeneron Pharmaceuticals

280 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02326220

The ClinicalTrials.gov registry entry for NCT02326220 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 248-participant average among 4 other Heterozygous Familial Hypercholesterolemia trials with a reported enrollment target (75% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heterozygous Familial Hypercholesterolemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02326220 reports 13 study locations spanning 9 distinct geographic areas - top geographies include Other, Colorado, Connecticut.

Frequently Asked Questions

What is clinical trial NCT02326220 about?

NCT02326220 is a clinical study titled "Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy". The primary objective of the study is to evaluate the effect of alirocumab 150 mg every 2 weeks (Q2W) in comparison with placebo on the frequency of low-density lipoprotein (LDL) apheresis treatments in participants with heterozygous familial hypercholesterolemia (HeFH) undergoing weekly or bi-weekl...

What is the current status of trial NCT02326220?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 62 participants. The study started on 2015-03-31. Estimated completion is 2016-04-30.

What conditions does trial NCT02326220 study?

This clinical trial studies the following conditions: Heterozygous Familial Hypercholesterolemia.

What interventions are being tested in trial NCT02326220?

The interventions under investigation include: Placebo (DRUG), Alirocumab (DRUG).

Who is sponsoring clinical trial NCT02326220?

This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02326220 being conducted?

This trial has 13 study locations across Colorado, Connecticut, Kansas, Maine, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heterozygous Familial Hypercholesterolemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heterozygous Familial Hypercholesterolemia

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.